Puri C P, Gopalkrishnan K, Iyer K S
Institute for Research in Reproduction, Indian Council of Medical Research, Parel, Mumbai.
Asian J Androl. 2000 Sep;2(3):179-90.
Considerable efforts have been made to develop a male contraceptive and the studies have provided very useful information in this field. At least five different strategies to develop a male contraceptive have been pursued, namely: inhibition of sperm production, interference with sperm function, interruption of sperm transport, prevention of sperm deposition, and prevention of sperm-egg interaction. Of all these approaches, inhibition of sperm production by using androgens either alone or in combination with progestins have given the most encouraging results. A number of clinical trials substantiate that it is indeed possible to have a reversible, effective and safe hormonal method of contraception. A postmeiotic and epididymal approach to interfere with sperm function or the secretory and metabolic processes of the epididymis is another attractive option of male contraceptive development. A number of chemical compounds have been identified which interfere with sperm function in the epididymis without affecting sperm production, however, the compounds evaluated so far were found to be toxic. Interruption of sperm transport through the vas either by vasectomy or percutaneous intravasal injection of liquids which form cure-in-place plugs is also an attractive option. However, reversibility of the methods is of concern in their wide scale use. The major constraint in developing a long-acting male contraceptive seems to be the need for greater investment for product development. The clinical trials for evaluating the efficacy and safety of the new products and formulations stretch over several years and require enormous financial commitment. Nevertheless, the long-term gain of having a long-acting reversible contraceptive for men is far greater than the financial commitments over few years. Male attitude towards using methods of family planning is much more favourable than originally believed. The pharmaceutical industry as well as the health care providers therefore have a greater responsibility. For early development of a contraceptive for men, it is essential to increase investment and simplify the drug regulatory procedures. The advent of newer technologies coupled with the convergent efforts of scientists will certainly make it possible to have an effective, safe and reversible male contraceptive in the near future.
为开发男性避孕药已付出了巨大努力,这些研究在该领域提供了非常有用的信息。至少已探索了五种不同的开发男性避孕药的策略,即:抑制精子生成、干扰精子功能、阻断精子运输、阻止精子沉积以及防止精卵相互作用。在所有这些方法中,单独使用雄激素或与孕激素联合使用来抑制精子生成取得了最令人鼓舞的结果。多项临床试验证实,确实有可能拥有一种可逆、有效且安全的激素避孕方法。一种减数分裂后和附睾途径来干扰精子功能或附睾的分泌和代谢过程是男性避孕药开发的另一个有吸引力的选择。已经鉴定出一些化合物,它们可干扰附睾中的精子功能而不影响精子生成,然而,迄今为止评估的这些化合物被发现有毒。通过输精管切除术或经皮向输精管内注射形成原位固化栓的液体来阻断精子通过输精管运输也是一个有吸引力的选择。然而,这些方法的可逆性在其广泛应用中令人担忧。开发长效男性避孕药的主要制约因素似乎是产品开发需要更多投资。评估新产品和制剂疗效与安全性的临床试验持续数年,需要巨大的资金投入。尽管如此,拥有一种长效可逆男性避孕药的长期收益远大于几年的资金投入。男性对使用计划生育方法的态度比原先认为的要积极得多。因此,制药行业以及医疗保健提供者负有更大的责任。为了男性避孕药的早期开发,增加投资并简化药品监管程序至关重要。新技术的出现以及科学家们的共同努力肯定会使在不久的将来拥有一种有效、安全且可逆的男性避孕药成为可能。